Holen Sie sich die Stockscreener-App
2.005
5.42%
-0.115
Handel nachbörslich:
2.01
0.005
+0.25%
Schlusskurs vom Vortag:
$2.12
Offen:
$2.01
24-Stunden-Volumen:
1.01M
Relative Volume:
1.56
Marktkapitalisierung:
$79.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-144.01M
KGV:
-0.50
EPS:
-4.01
Netto-Cashflow:
$-113.02M
1W Leistung:
-5.87%
1M Leistung:
-26.01%
6M Leistung:
-80.78%
1J Leistung:
-84.25%
1-Tages-Spanne:
$1.89
$2.21
1-Wochen-Bereich:
$1.86
$2.29
52-Wochen-Spanne:
$1.86
$13.66
Biomea Fusion Inc Stock (BMEA) Company Profile
Firmenname
Biomea Fusion Inc
Sektor
Branche
Telefon
(650) 980-9099
Adresse
900 MIDDLEFIELD ROAD, REDWOOD CITY
Vergleichen Sie BMEA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
2.005 | 79.65M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-09 | Eingeleitet | Edward Jones | Buy |
| 2024-09-27 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Hochstufung | Truist | Hold → Buy |
| 2024-08-29 | Eingeleitet | CapitalOne | Overweight |
| 2024-06-11 | Herabstufung | Truist | Buy → Hold |
| 2024-06-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Eingeleitet | Truist | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-26 | Herabstufung | Jefferies | Buy → Hold |
| 2023-05-12 | Eingeleitet | Barclays | Overweight |
| 2023-03-29 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2023-02-24 | Eingeleitet | Citigroup | Buy |
| 2022-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Jefferies | Buy |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten
Biomea Fusion stock hits 52-week low at $1.86 amid sharp decline - Investing.com Canada
Biomea Fusion stock hits 52-week low at $1.86 amid sharp decline By Investing.com - Investing.com South Africa
HC Wainwright Reduces Earnings Estimates for Biomea Fusion - Defense World
Barclays Issues Pessimistic Forecast for Biomea Fusion (NASDAQ:BMEA) Stock Price - Defense World
HC Wainwright Weighs in on Biomea Fusion Q1 Earnings - Defense World
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) - Yahoo Finance
Biomea Fusion’s Strategic Shift: A Year of Transformation - TipRanks
Biomea Fusion, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion Expands Team with Strategic Equity Compensation Package - Stock Titan
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) - Yahoo Finance
Biomea Fusion Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Biomea Fusion (NASDAQ:BMEA) Receives “Buy” Rating from HC Wainwright - Defense World
Biomea Fusion reports Q4 EPS (81c), consensus (93c) - TipRanks
Biomea Fusion, Inc. SEC 10-K Report - TradingView
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - The Manila Times
Breakthrough: Biomea's Diabetes Treatment Achieves Major Blood Sugar Control Milestone - Stock Titan
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) - Yahoo Finance
Virtu Financial LLC Makes New Investment in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Biomea Fusion (BMEA) to Release Earnings on Monday - Defense World
BIOMEA FUSION Earnings Preview: Recent $BMEA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Biomea Fusion Inc expected to post a loss of 92 cents a shareEarnings Preview - TradingView
Biomea Fusion stock hits 52-week low at $2.33 amid sharp decline By Investing.com - Investing.com South Africa
Biomea Fusion stock hits 52-week low at $2.33 amid sharp decline - Investing.com Australia
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of “Buy” by Brokerages - Defense World
Thomas Butler steps down as Biomea CEO - BioCentury
Biomea Fusion Appoints Michael Hitchcock Interim CEO - MarketScreener
Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO - Seeking Alpha
Biomea Fusion’s SWOT analysis: stock’s potential amid clinical trials By Investing.com - Investing.com Australia
Biomea Fusion names Mick Hitchcock to succeed Thomas Butler as interim CEO - TipRanks
Biomea Fusion Announces Leadership Transition - GlobeNewswire
Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug - Stock Titan
Strategy (MSTR) Executives Buy Company’s Preferred Stock - The Globe and Mail
Stocks in play: Trilogy Metals Inc. - The Globe and Mail
Biomea Fusion’s SWOT analysis: stock’s potential amid clinical trials - Investing.com India
Biomea Fusion announces presentation of icovamenib preclinical, clinical data - Yahoo Finance
Biomea Fusion Presents Promising Clinical Data on Icovamenib at ATTD 2025, Highlighting Its Potential as a Disease-Modifying Therapy for Type 2 Diabetes - Nasdaq
Icovamenib Treatment in Patients with Severe - GlobeNewswire
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose - Yahoo Finance
Investors who Lost Money on Biomea Fusion, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationBMEA - ACCESS Newswire
Biomea Fusion Insiders Recover Some Losses, Which Stand At US$91k - Yahoo
D. Boral Capital Reiterates “Buy” Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
Biomea Fusion stock hits 52-week low at $2.49 amid sharp decline - Investing.com
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Biomea Fusion, Inc. (BMEA) - accessnewswire.com
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion reports inducement grant under Nasdaq listing rule - TipRanks
How Biomea Fusion's Latest Employee Stock Grant Reflects Its Talent Acquisition Strategy - StockTitan
An Investigation Has Commenced on Behalf of Biomea Fusion, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BMEA Losses - ACCESS Newswire
Finanzdaten der Biomea Fusion Inc-Aktie (BMEA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):